C-QUALITY: cost and quality-of-life pharmacoeconomic analysis of antidepressants used in major depressive disorder in the regional Italian settings of Veneto and Sardinia

References

• BelmakerRHAgamGMajor depressive disorderN Engl J Med20083581556818172175
   PubMed Web of Science ®Google Scholar
• MathersCBoermaTMa FatDThe Global Burden of Disease: 2004 UpdateGeneva SwitzerlandWorld Health Organization2008 Available from: http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_full.pdfAccessed September 25, 2013
   Google Scholar
• ColomboGDi MatteoSBudget impact analysis in the treatment of major depressive disorder on Italian regions: the role of venlafaxineMilan, ItalyWHERE Medical Press Srl2009 [Italian]
   Google Scholar
• BattagliaADubiniAMannheimerRPancheriPDepression in the Italian community: epidemiology and socio-economic implicationsInt Clin Psychopharmacol200419313514215107655
   PubMed Web of Science ®Google Scholar
• GreenbergPEKesslerRCBirnbaumHGThe economic burden of depression in the United States: how did it change between 1990 and 2000?J Clin Psychiatry200364121465147514728109
   PubMed Web of Science ®Google Scholar
• StoudemireAFrankRHedemarkNKamletMBlazerDThe economic burden of depressionGen Hosp Psychiatry1986863873943491775
   PubMed Web of Science ®Google Scholar
• FrankLRevickiDASorensenSVThe economics of selective serotonin reuptake inhibitors in depression: a critical reviewCNS Drugs2001151598311465013
   PubMed Web of Science ®Google Scholar
• SéguinMLesageAChawkyNSuicide cases in New Brunswick from April 2002 to May 2003: the importance of better recognizing substance and mood disorder comorbidityCan J Psychiatry200651958158617007225
   PubMed Web of Science ®Google Scholar
• RapaportMHClaryCFayyadREndicottJQuality-of-life impairment in depressive and anxiety disordersAm J Psychiatry200516261171117815930066
   PubMed Web of Science ®Google Scholar
• PanzarinoPJNashDBCost-effective treatment of depression with selective serotonin reuptake inhibitorsAm J Manag Care20017217318411216334
   PubMed Web of Science ®Google Scholar
• CiprianiAFurukawaTASalantiGComparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysisLancet2009373966574675819185342
   PubMed Web of Science ®Google Scholar
• CiprianiASantilliCFurukawaTAEscitalopram versus other antidepressive agents for depressionCochrane Database Syst Rev20092CD00653219370639
   PubMed Web of Science ®Google Scholar
• AgugliaERavasioRSimonettiMPecchioliSMazzoleniFTreatment modalities for SSRI and SNRI in Italy in 2003–2009Curr Med Res Opin2012289110
   Web of Science ®Google Scholar
• WesslingARamsbergJDepression: the review of antidepressantsSolna, SwedenThe Dental and Pharmaceutical Benefits Agency2008 Available from: http://www.tlv.se/Upload/genomgangen/review-antidepressants.pdfAccessed September 25, 2013
   Google Scholar
• MencacciCDi SciascioGKatzPRipellinoCCost-effectiveness evaluation of escitalopram in major depressive disorder in ItalyClinicoecon Outcomes Res20135879923413176
   PubMedGoogle Scholar
• GaynesBRushAMadhukarTWisniewskiSSpencerDFavaMThe STAR*D study: treating depression in the real worldCleve Clin J Med2008751576618236731
   PubMed Web of Science ®Google Scholar
• HamiltonMA rating scale for depressionJ Neurol Neurosurg Psychiatry196023566214399272
   PubMed Web of Science ®Google Scholar
• MontgomerySAAsbergMA new depression scale designed to be sensitive to changeThe British Journal of Psychiatry1979134382389444788
   PubMed Web of Science ®Google Scholar
• GilchristGGunnJObservational studies of depression in primary care: what do we know?BMC Fam Pract200782817493280
   PubMed Web of Science ®Google Scholar
• LothgrenMHemelsMFrancoisCCost-effectiveness analysis of escitalopram as first line treatment of depression in SwedenPrim Care Psychiatry200494153162
   Web of Science ®Google Scholar
• KhanAKhanSRLeventhalRMBrownWASymptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: a replication analysis of the Food and Drug Administration DatabaseInt J Neuropsychopharmacol20014211311811466159
   PubMed Web of Science ®Google Scholar
• Agenzia Italiana del FarmacoRomeAgenzia Italiana del Farmaco Available from: http://www.agenziafarmaco.gov.it/Accessed November 21, 2012
   Google Scholar
• World Health Organization Collaborating CenterInternational language for drug utilization researchOslo, NorwayWorld Health Organization Collaborating Center for Drug Statistics Methodology Available from: http://www.whocc.no/Accessed November 21, 2012
   Google Scholar
• SobockiPEkmanMAgrenHRunesonBJonssonBThe mission is remission: health economic consequences of achieving full remission with antidepressant treatment for depressionInt J Clin Pract200660779179816846399
   PubMed Web of Science ®Google Scholar
• RobinsonRCost-utility analysisBMJ199330785924
   Google Scholar
• National Guideline Clearinghouse: DepressionThe treatment and management of depression in adultsGuideline summaryLondon, UKNational Institute for Health and Clinical Excellence2009 Available from: http://guideline.gov/content.aspx?id=15521Accessed December 17, 2012
   Google Scholar
• NordströmGDanchenkoNDespiegelNCost-effectiveness evaluation in Sweden of escitalopram compared with venlafaxine extended-release as first-line treatment in major depressive disorderValue Health201215223123922433753
   PubMed Web of Science ®Google Scholar
• RamsbergJAsseburgCHenrikssonMEffectiveness and cost-effectiveness of antidepressants in primary care: a multiple treatment comparison meta-analysis and cost-effectiveness modelPLoS One201278e4200322876296
   PubMed Web of Science ®Google Scholar
• NuijtenMBrignoneMMarteauFCost-effectiveness of escitalopram in major depressive disorder in Dutch health careClin Ther20123461364137822578310
   PubMed Web of Science ®Google Scholar
• DruaisSGauthierADemyttenaeareKAn assessment of the cost-effectiveness of escitalopram vs multiple comparators as first-line antidepressant in patients with major depressive disorder (MDD) in BelgiumPresented at the International Society for Pharmacoeconomics and Outcomes Research CongressBerlin, GermanyNovember 3–7, 2012
   Google Scholar
• EvansCThe use of consensus methods and expert panels in pharmacoeconomic studies: practical applications and methodological shortcomingsPharmacoeconomics1997122 Pt 112112910169665
   PubMed Web of Science ®Google Scholar